Clearbridge Investments LLC Sells 8,194 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Clearbridge Investments LLC trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 409,711 shares of the company’s stock after selling 8,194 shares during the quarter. Clearbridge Investments LLC’s holdings in Medpace were worth $136,118,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. R Squared Ltd bought a new stake in Medpace during the fourth quarter worth about $30,000. SBI Securities Co. Ltd. bought a new stake in shares of Medpace during the 4th quarter worth approximately $31,000. Jones Financial Companies Lllp boosted its position in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after acquiring an additional 110 shares in the last quarter. Lindbrook Capital LLC increased its stake in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after acquiring an additional 29 shares during the last quarter. Finally, True Wealth Design LLC raised its position in Medpace by 16,800.0% during the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MEDP has been the topic of a number of research analyst reports. Robert W. Baird raised their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Leerink Partnrs upgraded Medpace to a “hold” rating in a research report on Monday, March 24th. Finally, Leerink Partners began coverage on shares of Medpace in a report on Monday, March 24th. They issued a “market perform” rating and a $330.00 target price for the company. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $376.30.

Medpace Price Performance

Medpace stock opened at $312.36 on Monday. The business has a 50 day moving average of $335.90 and a 200-day moving average of $339.18. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The company has a market capitalization of $9.52 billion, a P/E ratio of 24.73, a P/E/G ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.